Table 1.
Reported changes quantified on functional magnetic resonance following neoadjuvant chemotherapy for breast cancer
| Functional technique and study | Responders | Non-responders | Time point imaged after NAC |
|---|---|---|---|
| DCE-MRI (percentage change in parameters) | |||
| Ah-See et al. [12] | Ktrans ↓39.8% | Ktrans ↑18.1% | 2 cycles |
| kep ↓33.3% | kep ↑7.4% | 2 cycles | |
| rBV ↓59.3% | rBV ↑73.4% | 2 cycles | |
| rBF ↓56.4% (n = 19) | rBF ↑70.6% (n = 19) | 2 cycles | |
| Pickles et al. [13] | Ktrans ↓19.7% | Ktrans ↓19.6% | 'At early time point' |
| kep ↓19.9% | kep ↓36.2% | ||
| ve ↑4.36% (n = 48) | ve ↑27.6% (n = 20) | ||
| Padhani et al. [15] | Ktrans ↓22% (n = 9) | Ktrans ↓6.5% (n = 6) | 1 cycle |
| Ktrans ↓62% (n = 7) | Ktrans ↓25% (n = 6) | 2 cycles | |
| DW-MRI (percentage change in ADC) | |||
| Pickles et al. [32] | ↑16% (n = 10) | NA | 1 cycle |
| ↑27% (n = 10) | NA | 2 cycles | |
| Sharma et al. [33] | ↑15% (n = 14) | NA | 1 cycle |
| ↑27% (n = 24) | NA | 2 cycles | |
| ↑35% (n = 29) | NA | 3 cycles | |
| Nilsen et al. [34] | ↑25% (n = 25) | NA | 4 cycles |
| R2* (change in s-1) | |||
| Li et al. [36] | ↑10% (n = 27) | NA | 2 cycles |
| MRS (percentage change in Cho SNR) | |||
| Jacobs et al. [46] | ↓35% (n = 15) | ↓11% (n = 3) | 1 cycle |
| 23Na MRI (percentage change in total sodium concentration) | |||
| Jacobs et al. [46] | ↓27% (n = 15) | ↓21% (n = 3) | 1 cycle |
ADC, apparent diffusion coefficient; Cho, choline; DCE, dynamic contrast-enhanced; DW, diffusion-weighted; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NA, sodium; NAC, neoadjuvant chemotherapy; rBF, relative blood flow; rBV, relative blood volume; SNR, signal-to-noise ratio.